Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P01CA087497-20)
Article History
Received: 26 August 2021
Revised: 7 March 2022
Accepted: 7 March 2022
First Online: 5 April 2022
Competing interests
: DH has no competing interests. AL is a founder, shareholder, receives fees from, and is a member of the board of directors of PMV pharmaceutical company, which produces small molecules that reactivate mutant p53 proteins. He also chairs the SAB of Janssen Pharmaceutical company and is a member of the board of Meira GTX, a gene therapy company for restoring eye sight. He is also a member of the board of directors of GeneCentric, a RNA seq diagnostic company for cancer treatments. He also receives funding from a grant from the NCI, P01CA087497-20. BG is a founder, and advisor of ROME, a company that explores the role of repetitive DNA sequences in cancers. AL is on the SAB of ROME.